Ämnen: Industri, tillverkning

Nordisk registerstudie på ADA: Behandling av typ 2-diabetes med SGLT-2-hämmare, jämfört med andra glukossänkande läkemedel, förknippas med en minskad risk för förtida död och hjärtsvikt

12 Juni 2017 08:45

Resultat från den nordiska delen av observationsstudien CVD-REAL, presenterades vid ADA, den 11 juni. Resultaten visar att behandling av typ 2-diabetes med SGLT2-hämmare i klinisk verklighet är associerad med en signifikant minskad risk för kardiovaskulära insjuknanden, särskilt med dödlig utgång, jämfört med andra glukossänkande läkemedel, även hos patienter utan känd hjärt-kärlsjukdom.

AstraZeneca presents new data underpinning safety profile and Real-World CV outcomes of Farxiga at ADA 2017

12 Juni 2017 08:03

Comprehensive updated analysis provides valuable evidence on the safety profile of Farxiga, including no imbalance in lower-limb amputations New analyses from CVD-REAL examine reductions in CV events for SGLT-2 inhibitors, including Farxiga in patients with and without CV disease versus DPP-4 inhibitors

AstraZeneca to present scientific advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions

8 Juni 2017 08:03

AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company’s Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga (dapagliflozin) and Bydureon(exenatide extended-release), with more than 50 abstracts at the American Diabetes Association’s (ADA) 77th Scientific Sessions in San Diego, USA, 9-13 June 2017

AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig

7 Juni 2017 09:13

AstraZeneca today announced that it has entered an agreement with Grünenthal for the global rights to Zomig(zolmitriptan) outside Japan

Lynparza significantly reduces the risk of disease worsening or death in patients with BRCA-mutated metastatic breast cancer

4 Juni 2017 13:30

AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with Lynparza (olaparib) tablets (300mg twice daily), compared to treatment with physician’s choiceof a standard of care chemotherapy.

AstraZeneca delivers new data on expanding portfolio of cancer medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

26 Maj 2017 08:03

AstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk

23 Maj 2017 08:07

AstraZeneca today announced top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial.

Phase III Zonda trial for benralizumab shows ability to reduce oral steroid use in severe asthma patients

22 Maj 2017 20:33

​Results from the Phase III ZONDA trial presented at the American Thoracic Society (ATS) 2017 International Congress demonstrated that adding benralizumab to standard of care allowed patients dependent on OCS to significantly reduce or discontinue steroids while maintaining asthma control.

AstraZeneca enters agreement with Recordati for Seloken in Europe

22 Maj 2017 08:02

​AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK

AstraZeneca to present scientific advancements from growing respiratory portfolio at the American Thoracic Society conference 2017

18 Maj 2017 08:05

AstraZeneca and its global biologics research and development arm, MedImmune, will present new data from its growing respiratory portfolio and pipeline at the 113th annual conference of the American Thoracic Society (ATS) in Washington, DC, USA, 19-24 May 2017

Stipendium till Katalin Dobra

12 Maj 2017 12:09

Idag tilldelas Universitetslektor Katalin Dobra, verksam vid Karolinska Institutet och Överläkare vid Karolinska Universitetssjukhuset, Svensk Förening för Patologis (SvFP), stipendie för 2017. Stipendiet uppmärksammar personer som bidrar med betydande insatser inom molekylärpatologisk diagnostik och har instiftats av Svensk Förening för Patologi (SvFP) och AstraZeneca.

Imfinzi significantly reduces the risk of disease worsening or death in the phase III pacific trial for stage III unresectable lung cancer

12 Maj 2017 08:05

Imfinzi met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer in a planned interim analysis

AstraZeneca provides update on STRATOS 1 phase III trial of tralokinumab in severe, uncontrolled asthma

10 Maj 2017 08:04

Tralokinumab did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate
Second pivotal Phase III trial STRATOS 2 is ongoing with results expected in second half of 2017
AstraZenecaand MedImmune, its global biologics research and development arm, today announced that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet i

Lungcancerstipendium till Dr Mikael Johansson

5 Maj 2017 18:39

Idag tilldelas Överläkare Mikael Johansson, verksam vid Cancercentrum, Norrlands Universitetssjukhus, SLUSG-stipendiet 2017. Stipendiet har instiftats av Svenska Lungcancerstudiegruppen (SLUSG) och AstraZeneca och uppmärksammar personer som bidrar med betydande insatser inom lungcancerområdet.

AstraZeneca PLC:s resultatrapport för första kvartalet 2017

27 April 2017 08:03

En positiv start med fortsatt nyhetsflöde kring vår forskningsportfölj i det som har potential att bli ett avgörande år för bolaget

Tagrisso receives full approval in the EU

25 April 2017 14:34

Full approval follows Tagrisso’s expedited Conditional Marketing Authorisation as first-in-class medicine for patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer

Tagrisso (osimertinib) receives US FDA full approval

31 Mars 2017 08:04

​Conversion from accelerated to full approval confirms the potential of Tagrissoto become standard of care in the US Approval based on Phase III AURA3 trial thatdemonstrated significant improvement in progression-free survival with Tagrisso as compared to chemotherapy

AstraZeneca’s potential medicine for Neuromyelitis Optica Spectrum Disorder receives orphan designation in Europe

29 Mars 2017 08:04

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Medicines Agency (EMA) has granted orphan designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

AstraZeneca to share its robust early science in Oncology with the medical community at AACR 2017

28 Mars 2017 08:03

60 abstracts from early oncology portfolio including 7 oral presentations, across Tumour Drivers and Resistance, Immuno-Oncology, Antibody-Drug Conjugates and DNA Damage Response Potential new medicines targeting cancer cell-death mechanisms highlight potential of emerging Tumour Drivers and Resistance research​

Tagrisso approved in China as first-in-class treatment for EGFR T790M mutation-positive metastatic non-small cell lung cancer

27 Mars 2017 13:11

First AstraZeneca medicine approved under China’s new Priority Review pathway Tagrisso is an important new medicine in a country where lung cancer is the leading cause of cancer-related deaths and EGFR-mutation rates are among highest globally